Pierrel SpA (PRL.MI) Stock Price

Pierrel SpA generates revenue through the registration and marketing of dental anesthetics under the Pierrel brand. The company operates in three segments: Contract Manufacturing, which develops and produces drugs like tube vials, bottles, ampoules, drops, sprays, tablets, and gels at its Capua facility; Pharma, which focuses on developing, registering, and licensing new drugs and medical devices; and Tech-driven Contract Research & Development Organization, which researches existing drugs for rare disease treatments. The Contract Manufacturing segment utilizes its Capua production facility with warehouses, laboratories, and offices to manufacture products, while the Pharma segment handles regulatory approvals and commercialization. The Tech-driven segment targets pharmaceutical companies seeking to repurpose existing drugs for rare conditions. Pierrel SpA's clients include pharmaceutical companies requiring contract manufacturing services, as well as entities seeking to develop or license new drugs and medical devices. The company's products are sold under the Pierrel brand for dental anesthetics, with the Contract Manufacturing segment producing a wide range of drug delivery formats. The Tech-driven segment collaborates with pharmaceutical firms to adapt existing drugs for rare disease applications, leveraging Pierrel's research capabilities. The Pharma segment's focus on registration and licensing ensures that new products meet regulatory standards before market entry. The company's revenue streams are derived from manufacturing services, drug development and licensing, and contract research for rare disease treatments. Dental anesthetics marketed under the Pierrel brand form a core product line, while the Contract Manufacturing segment provides essential production support for various drug formats. The Pharma segment's activities drive revenue through regulatory compliance and commercial partnerships, and the Tech-driven segment capitalizes on the growing demand for rare disease therapies by offering specialized research services.